Sinovac Biotech

Sinovac Biotech Ltd. is a holding company, which engages in the research, development, manufacture, and commercialization of vaccines that protect against human infectious diseases. The company is headquartered in Beijing, Beijing and currently employs 3,037 full-time employees. The company went IPO on 2009-11-13. The firm is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, hand foot and mouth disease (HFMD), seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza, coronavirus, pneumococcus, poliomyelitis, varicella and mumps. The firm's pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The firm is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The firm develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine.